I appreciate all the responses. I do remain skeptical, yet optimistic just because of the data released during the conferences on the so called "top line interim data clinical data". I guess the term "interim data" in itself should suggest the completed data and upcoming version two data will be better. This diagnostic test does have potential, but IMHO it seems more of a bridge to MANF than any huge revenue source. But hey theres a chance!